Cagrilintide news

All news on Cagrilintide (also known as AM833): plants, production capacities, investments and involved companies in Europe.

16 September 2025
Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results
Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.

Who will be producing Cagrilintide in the future?

Find out with chemXplore Analytics